Home Hero
Home Hero

For your patients’ severe
eosinophilic asthma

Help bring
back balance

By preventing exacerbations
& by reducing daily OCS dose

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.


lung icon

Exacerbation reduction

Trial 2: 53% reduction in exacerbations vs placebo
(P<0.001; Primary Endpoint)1*

Real-world study:

interim analysis at 1 year2

Lungs Icon



in exacerbations

vs baseline

Primary objective.

Results are descriptive.

See study limitations

Pill icon

OCS reduction

Trial 3: Greater reduction in daily OCS while maintaining asthma control vs placebo (P=0.008; Primary Endpoint; Weeks 20-24)3

Real-world study:

interim analysis at 1 year2

Lungs Icon



in daily maintenance
OCS dose vs baseline§

Secondary objective.

Results are descriptive.

See study limitations

calendar icon

Long-term data

4.5-year open-label study:
Exacerbation rate 0.68/year (Secondary Endpoint)4II

Associated with

Lungs Icon



in annual exacerbation

rate vs baseline4II

Results are descriptive.

Median duration 3.8 years.2

Real-world study: Prespecified interim analysis of a 2-year prospective, observational cohort study at 1 year (N=822). Primary objective (shown above): Post-exposure NUCALA 1.23 vs baseline 4.28 (71% reduction; rate ratio 0.29; 95% CI: 0.26, 0.32). Secondary objective (shown above): Daily median maintenance OCS dose in OCS-dependent patient subgroup (n=298). Post-exposure NUCALA at Weeks 53-56 (n=222) 2.5 mg/day vs baseline 10 mg/day. Results are descriptive. Study limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2

§Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.2


II4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Select secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.2,4 Results are descriptive.

*Trial 2: 32-week placebo controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001.

Trial 3: 24-week placebo-controlled OCS dose reduction trial (N=135).


The targeted therapy for 4 eosinophil-driven diseases

NUCALA is for the:

See Important Safety Info

Checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your SEA patients and practice

See patient access & support

NUCALA Autoinjector icon

Administering NUCALA 

NUCALA gives appropriate patients the option to self-administer at home.

See SEA dosing & administration

CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.